A new form of continuous combined hormone replacement therapy has become available that contains estradiol and drospirenone as the progestogen component. Drospirenone is a synthetic progestogen, the only one in hormone replacement therapy in the UK that possesses clinically relevant anti-mineralocorticoid activity. The combination of estradiol and drospirenone has been shown to provide relief from estrogen-deficiency symptoms of the menopause. It also helps to prevent osteoporosis in postmenopausal women by increasing bone density. Further, it has been shown to provide protection against endometrial hyperplasia associated with unopposed estrogen therapy.
Schering Health Care.Angeliq summary of product characteristics. June 2005
2.
RübigA. Drospirenone: a new cardiovascular-active progestin with anti-aldosterone and antiandrogenic properties. Climacteric2003; 6 (Suppl. 3): 49–54.
3.
FuhrmannU, KrattenmacherR, SlaterEP, FritzemeierKH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception1996; 54: 243–51.
4.
SchürmannR, HollerT, BendaN. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric2004; 7: 189–96.
5.
StrothmannA, SchneiderHPG. Hormone therapy: the European women's perspective. Climacteric2003; 6: 337–46.
6.
Sitruk-WareR. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging2004; 21: 865–83.
7.
WarmingL, RavnP, NielsenT, ChristiansenC. Safety and efficacy of drospirenone used in a continuous combination with 17-beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric2004; 7: 103–11.
8.
ArcherDF, ThorneycroftIH, FoeghM. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause2005; 12: 716–27.
